Medical Therapeutics

Axent Biosciences

Brief Description

Axent Biosciences is a pre-clinical stage biotechnology company developing next generation stem cell therapies to address unmet medical needs in human diseases/disorders. The company was spun out of research discoveries in the lab of UC Berkeley Professor of Chemical and Biomolecular Engineering, Bioengineering, and Neuroscience David Schaffer. Axent's platform technologies in stem cell manufacturing and implantation leverage 20+ years of stem cell expertise and 10+ years of biomaterials engineering to overcome major bottlenecks in the clinical development...

Addition Therapeutics

Brief Description

Addition is transforming genetic medicine by developing RNA-only therapeutics that PRINT™ any genetic element at specific safe harbor sites.

Timeline 2021. Company founded Inventors

Kathy Collins, Jeremy John McIntyre, Sarah Madeline Palm, Heather Upton, Briana Nicole Van Treeck. Xiaozhu Zhang

Berkeley BioSciences Inc.

Brief Description

Berkeley BioSciences, Inc. is a molecular immunology and oncology company with two divisions: biopharmaceutical and nutraceutical. It is researching and developing therapeutics and nutritional products based on patented naturally-occurring and biologically optimized phytonutrients with potent immune modulating and anti-cancer properties. The company was founded by Dr. Gary Firestone, former Chairman of the Nutritional Sciences Department and NIH Director of Cancer Research at UC Berkeley. The company's first...

Exelixis, Inc.

Brief Description

Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, the company established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. The company developed CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib) and COTELLIC® (cobimetinib), and partnered with leading...

Opus Biosciences

Brief Description

The mission of Opus Biosciences is to advance the field of lipid nanoparticle delivery through the development of safer, higher efficacy, cost effective, and exceedingly efficient LNPs, surpassing industry standards. Opus is committed to unlocking existing limitations within the drug delivery space by enabling more frequent re-dosing, reducing toxicity, and improving and expanding therapeutic targets. The foundational technology was invented in the lab of Bioengineering Professor Niren Murthy at the UC Berkeley Innovative Genomics Institute.

Timeline 2023....

Ambrx Inc.

Brief Description Ambrx®, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein-based therapeutics using an expanded genetic code. Unlike conventional conjugation techniques that create a mixture of suboptimal molecules, Ambrx technology combines site specific conjugation with proprietary linkers, payloads and pharmacokinetic extenders to create a single molecular species that is optimized for safety, efficacy and biophysical properties. We call this process Protein Medicinal Chemistry™.

Protein Medicinal Chemistry™ can optimize any protein or antibody to...

RM2

BRIEF DESCRIPTION

Wound treatment.

INVENTOR

Mary Phillips, Paul Mikus, and Boris Rubinsky

Receptron, Inc.

Brief Description

Receptron, Inc. was founded to develop hormone receptor technology that modulates the endogenous thrombopoietin (TPO) receptor, a human hormone that stimulates patelet production.

Timeline 1987. Company founded Inventors

Andrea Goldsmith, Robert Goodenow, Lennart Olsson

Narra Biosciences, LLC

Brief Description

Narra Biosciences develops anti-cancer therapeutics based on anti-cancer properties of the soybean protein Lunasin (from the Tagalog word "lunas" for cure. The technology can be used to identify potential drug targets and diagnostic biomarkers, and also as a research tool for understanding epigenetic control of gene expression during cancer development. The company was founded by UC Berkeley Nutritional Science and Toxicology Professor Ben de Lumen based on research discoveries in his lab.

Timeline 2015. Company founded Inventors

Benito de Lumen,...

KaRNAteq, Inc.

BRIEF DESCRIPTION

KaRNATeq develops tools for RNA sequencing that are the next step forward in genomics. The enzymes developed by the company enable doctors and scientists to capture more information at reduced cost.

INVENTOR

Kathleen Collins